## **January Newsletter**

#### 🕤 💽 in

Where Life-changing Therapies Turn First™

Volume 12, Issue 1

Join us February 24<sup>th</sup>-28<sup>th</sup> for a week of educational WebEx trainings in celebration of <u>Rare Disease Day</u> (February 28<sup>th</sup>).

CTI CLINICAL TRIAL & CONSULTING

Click here for more information and to register!

# Upcoming Meetings CTI will be Attending ...

9<sup>th</sup> Annual New York Stem Cell Summit New York, NY February 18 Timothy Schroeder, CEO, to present

> GTC's 2<sup>nd</sup> Orphan Drug Research and Commercialization San Diego, CA February 20-21

Biocom's Global Life Science Partnering Conference San Diego, CA February 26-27

If you are interested in scheduling a meeting with CTI, please contact Nick Schatzman at 513-598-9290 or at nschatzman@ctifacts.com

### CTI's Clinical Research Associates are "Best CRAs to Work With"


Clinical monitoring coverage for CTI, across all locations, is built around the philosophy of providing therapeutic expertise to our sponsors. CTI Clinical Research Associates (CRAs) have significant experience working with complex studies and critically ill patients. Our staff carries decades of experience in research and nursing outside of their CRA experience. With an average retention rate of over 95%, our CRAs are able to see their studies through from start-up to close-out.

In order to ensure the highest level of quality, CTI conducts an annual CRA survey. The 2013 survey was directed to nearly 200 research coordinators that currently work with or have worked with CTI CRAs in the past year. Feedback was solicited in the form of 7 questions, 5 of which asked the coordinators to rate the CRA from 1 to 5 (1 being excellent and 5 needs improvement) on various items such as:

- Protocol/Therapeutic Knowledge
- Ability to Collaborate
- Responsiveness
- Communication
- Overall Performance

This year's survey had an excellent response rate (over 64%) and an overall rating score of 1.29 for the questions in the above categories.

Below is a comparison of survey questions over the past five years, in which the CTI CRA group has continually grown. Throughout this growth, CTI CRAs have consistently achieved an overall performance rating of excellent (1.3 on a 5 point scale), proving that study site personnel continually rank CTI CRAs among the best in the business.



look forward to working together again!

<u>Emai</u>

Join Our Mailing List!

For additional information about CTI's CRAs, please contact:

John Williams Assistant Director, Clinical Monitoring jwilliams@ctifacts.com

#### About CTI

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.